

Intelligent Ultrasound Group plc  
(the "Group" or the "Company")

**Notice of results**  
*Analyst and investor briefing*

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces it will issue its audited final results for the year ended 31 December 2023 on Wednesday, 1 May 2024.

A briefing for analysts will be held via Teams on 1 May 2024 at 9.30am. To register, please contact [intelligentultrasound@tbcardew.com](mailto:intelligentultrasound@tbcardew.com)

The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 1 May at 1pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet the Company via: <https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor>

Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited.

**For further information, please contact:**

**Intelligent Ultrasound Group plc**

Stuart Gall, CEO

Helen Jones, CFO

[www.intelligentultrasound.com](http://www.intelligentultrasound.com)

Tel: +44 (0)29 2075 6534

**Cavendish Capital Markets Limited**  
**(Nominated advisor and broker)**

Giles Balleny (Corporate Finance)

Nigel Birks (ECM)

Dale Bellis (Sales)

Tel: +44 (0)20 7397 8900

**TB Cardew - PR Advisors**

Ed Orlebar

Allison Connolly

Emma Pascoe-Watson

Jessica Pilling

[Intelligentultrasound@tbcardew.com](mailto:Intelligentultrasound@tbcardew.com)

Tel: +44 (0)7738 724630

Tel: +44 (0)7587 453955

Tel: +44 (0)7774 620415

Tel: +44 (0)7918 584573

**About Intelligent Ultrasound Group**

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

**Simulation**

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,700 simulators have been sold to over 800 medical institutions around the world.

#### **Clinical AI software**

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE HealthCare's SonoLyst software that is incorporated in their Voluson Expert and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.

[www.intelligentultrasound.com](http://www.intelligentultrasound.com)

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA but is not available for sale in any other territory requiring government approval for this type of product.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORMZGMDNRVGDZM